Jowan Al-Nusair
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jowan Al-Nusair has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
Mahmoud Abdallah
Department of Oncology, Edwards Comprehensive Cancer Institute, Marshall University, Huntington, WV 25701, USA
5 shared publicationsMohamed Alshal
Marshall University Joan C. Edwards School of Medicine, Huntington, WV, USA
5 shared publications- Thomas Wright
Internal Medicine Department, Joan Edwards School of Medicine, Erma Ora Byrd Center, Marshall University, Huntington, WV, USA
3 shared publications Toni Pacioles
Department of Oncology, Edwards Comprehensive Cancer Institute, Marshall University, Huntington, WV 25701, USA
3 shared publicationsMuhammad Omer Jamil
Department of Oncology, Edwards Comprehensive Cancer Institute, Marshall University, Huntington, WV 25701, USA
2 shared publications- Reesha Bodiwala
Marshall University Joan C Edwards School of Medicine Department of Internal Medicine, Huntington, WV, USA
2 shared publications
Latest Publications
- Open Access
New-Onset Heart Failure in Patients with Obesity using Tirzepatide or Semaglutide
Background: Tirzepatide and semaglutide improve functional status and heart failure (HF) events in patients with obesity and HF with preserved ejection fraction. Tirzepatide has been associated with greater control of cardiometabolic risk factors in patients with obesity compared to semaglutide. Whether tirzepatide is associated with lower risk of new-onset HF than semaglutide in patients with obesity is underexplored. Methods: A retrospective cohort study was conducted using data pooled from the TriNetX platform. Patients with obesity who initiated therapy with tirzepatide or semaglutide during the period Jun 4, 2021 to Aug 13, 2026 were identified and 1:1 propensity-score matched to produce two study cohorts. The one-year incidence of new-onset HF was calculated and compared between the two cohorts. Secondary outcomes included new-onset systolic HF, new-onset diastolic heart failure, new-onset atrial fibrillation or flutter, all-cause mortality, and hospital encounters. Cox proportional hazards models were fitted to calculate hazard ratios (HR) along with 95% confidence intervals (CI). Results: Two well-matched cohorts (N=424,269 in each) were formed. The incidence of new-onset HF was lower in the tirzepatide group (1.0% vs. 1.3%; absolute risk difference −0.3%, 95% CI −0.35 to −0.26; HR 0.9, 95% CI 0.86─0.93). The tirzepatide group were also at lower risk of all-cause mortality (HR, 95% CI: 0.8, 0.77─0.91) and new-onset systolic HF (0.8, 0.79─0.92). All other secondary outcomes occurred at similar rates in both study groups. Conclusion: Among patients with obesity, tirzepatide therapy was associated with lower risk of new-onset HF compared to semaglutide although the effect sizes were modest.
Open AccessNew-Onset Heart Failure in Patients with Obesity using Tirzepatide or Semaglutide
Background: Tirzepatide and semaglutide improve functional status and heart failure (HF) events in patients with obesity and HF with preserved ejection fraction. Tirzepatide has been associated with greater control of cardiometabolic risk factors in patients with obesity compared to semaglutide. Whether tirzepatide is associated with lower risk of new-onset HF than semaglutide in patients with obesity is underexplored. Methods: A retrospective cohort study was conducted using data pooled from the TriNetX platform. Patients with obesity who initiated therapy with tirzepatide or semaglutide during the period Jun 4, 2021 to Aug 13, 2026 were identified and 1:1 propensity-score matched to produce two study cohorts. The one-year incidence of new-onset HF was calculated and compared between the two cohorts. Secondary outcomes included new-onset systolic HF, new-onset diastolic heart failure, new-onset atrial fibrillation or flutter, all-cause mortality, and hospital encounters. Cox proportional hazards models were fitted to calculate hazard ratios (HR) along with 95% confidence intervals (CI). Results: Two well-matched cohorts (N=424,269 in each) were formed. The incidence of new-onset HF was lower in the tirzepatide group (1.0% vs. 1.3%; absolute risk difference −0.3%, 95% CI −0.35 to −0.26; HR 0.9, 95% CI 0.86─0.93). The tirzepatide group were also at lower risk of all-cause mortality (HR, 95% CI: 0.8, 0.77─0.91) and new-onset systolic HF (0.8, 0.79─0.92). All other secondary outcomes occurred at similar rates in both study groups. Conclusion: Among patients with obesity, tirzepatide therapy was associated with lower risk of new-onset HF compared to semaglutide although the effect sizes were modest.
- 16 October 2025
- Published by Elsevier in Blood Reviews
- Vol. 74, 101340
Artificial intelligence in myeloid malignancies: Clinical applications of machine learning in myelodysplastic syndromes and acute myeloid Leukemia
- 16 October 2025
- Published by Elsevier in Blood Reviews
- Vol. 74, 101340
Artificial intelligence in myeloid malignancies: Clinical applications of machine learning in myelodysplastic syndromes and acute myeloid Leukemia
- Open Access
- 1 August 2025
- Published by Elmer Press, Inc. in Journal of Hematology
- Vol. 14 (4) , 214-222
Efficacy and Safety of Momelotinib in Myelofibrosis: A Systematic Review and Meta-Analysis With a Focus on Anemia Outcomes
Background: Myelofibrosis (MF) can be primary (PMF) or secondary (SMF), with PMF driven by Janus kinases-signal transducer and activator of transcription proteins (JAK-STAT) pathway activation due to Janus kinase 2 (JAK2), the thrombopoietin receptor gene (myeloproliferative leukemia virus oncogene (MPL)), or calreticulin (CALR) mutations. Nearly 50% of PMF patients experience anemia (hemoglobin (Hb) < 10 g/dL), often worsened by JAK inhibitors like ruxolitinib and fedratinib. Momelotinib, an oral ACVR1, JAK1, and JAK2 inhibitor, improves anemia, symptoms, and splenomegaly, likely through hepcidin regulation. This review evaluates its efficacy and safety, with a focus on anemia. Methods: A systematic review and meta-analysis were conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, including randomized controlled trials (RCTs) and clinical studies assessing momelotinib’s efficacy and safety. Primary outcomes included spleen volume reduction (≥ 35%) and anemia response (transfusion independence). Secondary endpoints included symptom burden reduction and safety. Results: Six studies, including three RCTs, met inclusion criteria. Meta-analysis showed momelotinib was noninferior to ruxolitinib in spleen volume reduction but superior in anemia benefits, increasing transfusion independence (odds ratio (OR): 2.09; 95% confidence interval (CI): 1.53 - 2.85) and reducing transfusion dependence (OR: 0.62; 95% CI: 0.45 - 0.84). Symptom burden reduction was comparable to other JAK inhibitors. Common adverse events included dizziness (OR: 1.70; 95% CI: 1.05 - 2.74) and nausea (OR: 3.07; 95% CI: 1.82 - 5.18), with no significant increase in serious adverse events. Conclusions: Momelotinib improved anemia-related outcomes and quality of life in MF without increased adverse events. However, heterogeneity in control groups limited direct efficacy comparisons. Larger studies are needed to confirm its effectiveness and safety.
- 1 August 2025
- Published by Elmer Press, Inc. in Journal of Hematology
- Vol. 14 (4) , 214-222
Open AccessEfficacy and Safety of Momelotinib in Myelofibrosis: A Systematic Review and Meta-Analysis With a Focus on Anemia Outcomes
Background: Myelofibrosis (MF) can be primary (PMF) or secondary (SMF), with PMF driven by Janus kinases-signal transducer and activator of transcription proteins (JAK-STAT) pathway activation due to Janus kinase 2 (JAK2), the thrombopoietin receptor gene (myeloproliferative leukemia virus oncogene (MPL)), or calreticulin (CALR) mutations. Nearly 50% of PMF patients experience anemia (hemoglobin (Hb) < 10 g/dL), often worsened by JAK inhibitors like ruxolitinib and fedratinib. Momelotinib, an oral ACVR1, JAK1, and JAK2 inhibitor, improves anemia, symptoms, and splenomegaly, likely through hepcidin regulation. This review evaluates its efficacy and safety, with a focus on anemia. Methods: A systematic review and meta-analysis were conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, including randomized controlled trials (RCTs) and clinical studies assessing momelotinib’s efficacy and safety. Primary outcomes included spleen volume reduction (≥ 35%) and anemia response (transfusion independence). Secondary endpoints included symptom burden reduction and safety. Results: Six studies, including three RCTs, met inclusion criteria. Meta-analysis showed momelotinib was noninferior to ruxolitinib in spleen volume reduction but superior in anemia benefits, increasing transfusion independence (odds ratio (OR): 2.09; 95% confidence interval (CI): 1.53 - 2.85) and reducing transfusion dependence (OR: 0.62; 95% CI: 0.45 - 0.84). Symptom burden reduction was comparable to other JAK inhibitors. Common adverse events included dizziness (OR: 1.70; 95% CI: 1.05 - 2.74) and nausea (OR: 3.07; 95% CI: 1.82 - 5.18), with no significant increase in serious adverse events. Conclusions: Momelotinib improved anemia-related outcomes and quality of life in MF without increased adverse events. However, heterogeneity in control groups limited direct efficacy comparisons. Larger studies are needed to confirm its effectiveness and safety.
- Open Access
- 31 May 2025
- Published by SAGE Publications in Journal of Investigative Medicine High Impact Case Reports
- Vol. 13
The Imitation Game: Melanoma Metastasis Poses as a Primary Breast Tumor
Metastatic melanoma to the breast is a rare phenomenon often mistaken for primary breast cancer due to overlapping clinical and imaging characteristics. We report the case of a 51-year-old woman with a history of melanoma resected 7 years earlier, presenting with severe left hip pain and a 6-month history of a right breast lump. Imaging revealed extensive metastatic disease, including lesions in the femoral head, breast, lung, adrenal gland, and thoracic spine. Pathologic examination of the hip lesion obtained during total arthroplasty, as well as biopsies of the breast and lung, confirmed metastatic melanoma. Histology revealed pleomorphic tumor cells with necrosis, while immunohistochemical analysis demonstrated SOX10 and S100 positivity, confirming the diagnosis. Genetic testing identified microsatellite stability with a tumor mutational burden of 16 mutations per mega base. This case shows the importance of thorough cancer histories and the use of immunohistochemical staining to distinguish metastatic melanoma from primary breast malignancies. Despite timely diagnosis and intervention, the patient’s condition deteriorated rapidly, reflecting the aggressive nature of metastatic melanoma. This case highlights the need for vigilance in patients with a history of melanoma presenting with new breast masses to ensure accurate diagnosis and appropriate management.
- 31 May 2025
- Published by SAGE Publications in Journal of Investigative Medicine High Impact Case Reports
- Vol. 13
Open AccessThe Imitation Game: Melanoma Metastasis Poses as a Primary Breast Tumor
Metastatic melanoma to the breast is a rare phenomenon often mistaken for primary breast cancer due to overlapping clinical and imaging characteristics. We report the case of a 51-year-old woman with a history of melanoma resected 7 years earlier, presenting with severe left hip pain and a 6-month history of a right breast lump. Imaging revealed extensive metastatic disease, including lesions in the femoral head, breast, lung, adrenal gland, and thoracic spine. Pathologic examination of the hip lesion obtained during total arthroplasty, as well as biopsies of the breast and lung, confirmed metastatic melanoma. Histology revealed pleomorphic tumor cells with necrosis, while immunohistochemical analysis demonstrated SOX10 and S100 positivity, confirming the diagnosis. Genetic testing identified microsatellite stability with a tumor mutational burden of 16 mutations per mega base. This case shows the importance of thorough cancer histories and the use of immunohistochemical staining to distinguish metastatic melanoma from primary breast malignancies. Despite timely diagnosis and intervention, the patient’s condition deteriorated rapidly, reflecting the aggressive nature of metastatic melanoma. This case highlights the need for vigilance in patients with a history of melanoma presenting with new breast masses to ensure accurate diagnosis and appropriate management.
- Open Access
- 26 May 2025
- Published by SAGE Publications in Journal of Investigative Medicine High Impact Case Reports
- Vol. 13
Nodal Mature Plasmacytoid Dendritic Cell Proliferation in a Patient With Chronic Myelomonocytic Leukemia: A Diagnostic Mimic of Blastic Plasmacytoid Dendritic Cell Neoplasm
Mature plasmacytoid dendritic cell proliferation (MPDCP) is a rare, clonal but nonmalignant entity often associated with myeloid neoplasms such as chronic myelomonocytic leukemia (CMML), myelodysplastic syndromes, and acute myeloid leukemia. While typically confined to the bone marrow, nodal MPDCP is exceedingly rare and may mimic blastic plasmacytoid dendritic cell neoplasm (BPDCN), posing diagnostic challenges. We report a 78-year-old male with CMML-1 and progressive cervical lymphadenopathy. Workup revealed monocytosis, ASXL1 and CBL mutations, and CMML. Lymph node biopsy showed paracortical expansion by small mononuclear cells with plasmacytoid features. Immunophenotyping identified a CD4+, CD123+, CD303+, HLA-DR+, lysozyme+, CD56− population, consistent with MPDCP. A subset expressed TdT and granzyme B, with a Ki-67 index of 20% to 30%. Next-generation sequencing confirmed the same ASXL1 and CBL mutations in the lymph node, supporting clonal relation to CMML. Key differential diagnoses included BPDCN, T-cell lymphomas, Langerhans cell histiocytosis, and Kikuchi–Fujimoto disease. Absence of CD56, mature cytomorphology, and molecular concordance favored MPDCP. This case highlights the importance of distinguishing nodal MPDCP from malignant mimics. MPDCP may reflect immune evasion, altered cytokine signaling, or clonal progression in myeloid neoplasms. The patient was initially treated with hydroxyurea, later transitioned to decitabine/cedazuridine (Inqovi) for disease progression. Follow-up marrow biopsy showed stable CMML-2 with persistent mutations, and the patient remains under close monitoring. Recognizing MPDCP in unusual locations is critical for accurate diagnosis and prognostication. Further studies are warranted to clarify its molecular pathogenesis and potential as a biomarker of disease evolution in CMML and related disorders.
- 26 May 2025
- Published by SAGE Publications in Journal of Investigative Medicine High Impact Case Reports
- Vol. 13
Open AccessNodal Mature Plasmacytoid Dendritic Cell Proliferation in a Patient With Chronic Myelomonocytic Leukemia: A Diagnostic Mimic of Blastic Plasmacytoid Dendritic Cell Neoplasm
Mature plasmacytoid dendritic cell proliferation (MPDCP) is a rare, clonal but nonmalignant entity often associated with myeloid neoplasms such as chronic myelomonocytic leukemia (CMML), myelodysplastic syndromes, and acute myeloid leukemia. While typically confined to the bone marrow, nodal MPDCP is exceedingly rare and may mimic blastic plasmacytoid dendritic cell neoplasm (BPDCN), posing diagnostic challenges. We report a 78-year-old male with CMML-1 and progressive cervical lymphadenopathy. Workup revealed monocytosis, ASXL1 and CBL mutations, and CMML. Lymph node biopsy showed paracortical expansion by small mononuclear cells with plasmacytoid features. Immunophenotyping identified a CD4+, CD123+, CD303+, HLA-DR+, lysozyme+, CD56− population, consistent with MPDCP. A subset expressed TdT and granzyme B, with a Ki-67 index of 20% to 30%. Next-generation sequencing confirmed the same ASXL1 and CBL mutations in the lymph node, supporting clonal relation to CMML. Key differential diagnoses included BPDCN, T-cell lymphomas, Langerhans cell histiocytosis, and Kikuchi–Fujimoto disease. Absence of CD56, mature cytomorphology, and molecular concordance favored MPDCP. This case highlights the importance of distinguishing nodal MPDCP from malignant mimics. MPDCP may reflect immune evasion, altered cytokine signaling, or clonal progression in myeloid neoplasms. The patient was initially treated with hydroxyurea, later transitioned to decitabine/cedazuridine (Inqovi) for disease progression. Follow-up marrow biopsy showed stable CMML-2 with persistent mutations, and the patient remains under close monitoring. Recognizing MPDCP in unusual locations is critical for accurate diagnosis and prognostication. Further studies are warranted to clarify its molecular pathogenesis and potential as a biomarker of disease evolution in CMML and related disorders.
- Open Access
- 1 May 2025
- Published by SAGE Publications in Journal of Investigative Medicine High Impact Case Reports
- Vol. 13
Beyond The Usual Suspects: Primary Breast Lymphoma Incidentally Detected With Routine Mammographic Screening
Primary breast lymphoma (PBL) is a rare type of non-Hodgkin’s lymphoma, comprising less than 1% of all lymphomas and 0.5% of breast malignancies. The majority of PBL cases are of B-cell origin, with diffuse large B-cell lymphoma (DLBCL) being the most common subtype, though follicular lymphoma (FL) also occurs. We present a case of a 74-year-old woman whose routine mammogram revealed a 1.5 cm mass in the right breast. Ultrasound and biopsy confirmed the presence of classic follicular lymphoma, with B-cell markers CD20, CD10, Bcl-6, and Bcl-2. A PET scan and biopsy of the left periaortic lymph node identified additional disease, confirming stage III FL. The patient was asymptomatic and exhibited favorable prognostic factors, including normal beta-2 microglobulin and LDH levels. Due to the indolent nature of her disease and low tumor burden, the decision was made to pursue active surveillance rather than immediate treatment. This case highlights the diagnostic challenges of PBL and the importance of personalized management, particularly in asymptomatic patients with low disease burden.
- 1 May 2025
- Published by SAGE Publications in Journal of Investigative Medicine High Impact Case Reports
- Vol. 13
Open AccessBeyond The Usual Suspects: Primary Breast Lymphoma Incidentally Detected With Routine Mammographic Screening
Primary breast lymphoma (PBL) is a rare type of non-Hodgkin’s lymphoma, comprising less than 1% of all lymphomas and 0.5% of breast malignancies. The majority of PBL cases are of B-cell origin, with diffuse large B-cell lymphoma (DLBCL) being the most common subtype, though follicular lymphoma (FL) also occurs. We present a case of a 74-year-old woman whose routine mammogram revealed a 1.5 cm mass in the right breast. Ultrasound and biopsy confirmed the presence of classic follicular lymphoma, with B-cell markers CD20, CD10, Bcl-6, and Bcl-2. A PET scan and biopsy of the left periaortic lymph node identified additional disease, confirming stage III FL. The patient was asymptomatic and exhibited favorable prognostic factors, including normal beta-2 microglobulin and LDH levels. Due to the indolent nature of her disease and low tumor burden, the decision was made to pursue active surveillance rather than immediate treatment. This case highlights the diagnostic challenges of PBL and the importance of personalized management, particularly in asymptomatic patients with low disease burden.
- Open Access
- 4 April 2025
- Published by SAGE Publications in Journal of Investigative Medicine High Impact Case Reports
- Vol. 13
The Challenging and Unique Diagnosis of VEXAS Syndrome: A Case Report
VEXAS syndrome, a myeloid-driven autoinflammatory disorder associated with somatic mutations in the UBA1 gene, was first described in 2020 and presents significant diagnostic challenges due to its complex clinical features, including hematological abnormalities and autoimmune manifestations. We describe a case involving a 64-year-old male presenting with persistent anemia, weight loss, fatigue, fever, and recurrent inflammatory symptoms. Diagnostic workup, including imaging, serology, and bone marrow biopsy, revealed characteristic findings, including myeloid hyperplasia, and vacuolization in precursor cells. Genetic testing identified a UBA1 gene mutation, solidifying the diagnosis of VEXAS syndrome. The patient responded to immunosuppressive treatment with prednisone and ruxolitinib, with significant improvement in symptoms. This case tells us the importance of considering VEXAS syndrome in patients with refractory systemic inflammation and hematological abnormalities, particularly in older males. Early recognition and genetic testing are crucial for guiding treatment decisions, as the condition is progressive, often relapsing, and requires multidisciplinary management.
- 4 April 2025
- Published by SAGE Publications in Journal of Investigative Medicine High Impact Case Reports
- Vol. 13
Open AccessThe Challenging and Unique Diagnosis of VEXAS Syndrome: A Case Report
VEXAS syndrome, a myeloid-driven autoinflammatory disorder associated with somatic mutations in the UBA1 gene, was first described in 2020 and presents significant diagnostic challenges due to its complex clinical features, including hematological abnormalities and autoimmune manifestations. We describe a case involving a 64-year-old male presenting with persistent anemia, weight loss, fatigue, fever, and recurrent inflammatory symptoms. Diagnostic workup, including imaging, serology, and bone marrow biopsy, revealed characteristic findings, including myeloid hyperplasia, and vacuolization in precursor cells. Genetic testing identified a UBA1 gene mutation, solidifying the diagnosis of VEXAS syndrome. The patient responded to immunosuppressive treatment with prednisone and ruxolitinib, with significant improvement in symptoms. This case tells us the importance of considering VEXAS syndrome in patients with refractory systemic inflammation and hematological abnormalities, particularly in older males. Early recognition and genetic testing are crucial for guiding treatment decisions, as the condition is progressive, often relapsing, and requires multidisciplinary management.
- 28 March 2025
- Published by Harborside Press, LLC in Journal of the National Comprehensive Cancer Network
- Vol. 23 (3.5)
CLO25-084: Metastatic Neck Involvement in Oral Squamous Cell Carcinoma: A Retrospective Clinicopathological Study
"CLO25-084: Metastatic Neck Involvement in Oral Squamous Cell Carcinoma: A Retrospective Clinicopathological Study" published on 28 Mar 2025 by National Comprehensive Cancer Network.
- 28 March 2025
- Published by Harborside Press, LLC in Journal of the National Comprehensive Cancer Network
- Vol. 23 (3.5)
CLO25-084: Metastatic Neck Involvement in Oral Squamous Cell Carcinoma: A Retrospective Clinicopathological Study
"CLO25-084: Metastatic Neck Involvement in Oral Squamous Cell Carcinoma: A Retrospective Clinicopathological Study" published on 28 Mar 2025 by National Comprehensive Cancer Network.
- Open Access
- 27 January 2025
- Published by SAGE Publications in Journal of Investigative Medicine High Impact Case Reports
- Vol. 13
Complement-Mediated Hemolytic Uremic Syndrome Due to MCP/CD46 Mutation: A Case Report
Thrombotic microangiopathy (TMA) is a severe condition characterized by microangiopathic hemolytic anemia, thrombocytopenia, and end-organ damage, often involving the kidneys. Complement-mediated hemolytic uremic syndrome (cHUS), a rare form of TMA, arises from dysregulated alternative complement pathway activation, frequently due to genetic mutations. We report the case of a 23-year-old male presenting with TMA secondary to a heterozygous mutation in the membrane cofactor protein (MCP/CD46) gene. The patient exhibited severe renal and cardiovascular complications, including acute kidney injury requiring hemodialysis, uremic pericarditis, and persistent anemia. Diagnostic evaluation confirmed complement dysregulation, and management with eculizumab, plasmapheresis, and hemodialysis was initiated. Renal biopsy revealed classic TMA features, and genetic testing identified the MCP mutation, underscoring the importance of genetic predispositions in guiding diagnosis and therapy. This case emphasizes the critical role of genetic testing in TMA evaluation and highlights the potential for improved outcomes through targeted complement inhibition and individualized care strategies.
- 27 January 2025
- Published by SAGE Publications in Journal of Investigative Medicine High Impact Case Reports
- Vol. 13
Open AccessComplement-Mediated Hemolytic Uremic Syndrome Due to MCP/CD46 Mutation: A Case Report
Thrombotic microangiopathy (TMA) is a severe condition characterized by microangiopathic hemolytic anemia, thrombocytopenia, and end-organ damage, often involving the kidneys. Complement-mediated hemolytic uremic syndrome (cHUS), a rare form of TMA, arises from dysregulated alternative complement pathway activation, frequently due to genetic mutations. We report the case of a 23-year-old male presenting with TMA secondary to a heterozygous mutation in the membrane cofactor protein (MCP/CD46) gene. The patient exhibited severe renal and cardiovascular complications, including acute kidney injury requiring hemodialysis, uremic pericarditis, and persistent anemia. Diagnostic evaluation confirmed complement dysregulation, and management with eculizumab, plasmapheresis, and hemodialysis was initiated. Renal biopsy revealed classic TMA features, and genetic testing identified the MCP mutation, underscoring the importance of genetic predispositions in guiding diagnosis and therapy. This case emphasizes the critical role of genetic testing in TMA evaluation and highlights the potential for improved outcomes through targeted complement inhibition and individualized care strategies.
- Open Access
Evaluation of Anti-Angiogenic Therapy Combined with Immunotherapy and Chemotherapy as a Strategy to Treat Locally Advanced and Metastatic Non-Small-Cell Lung Cancer
Immunotherapy has made recent improvements in disease-free survival (DFS) and/or overall survival (OS) in all stages of non-small-cell lung cancer (NSCLC). Here, we review the tumor microenvironment and its immunosuppressive effects and discuss how anti-angiogenic therapies may potentiate the anti-carcinogenic effects of immunotherapy. We also review all the past literature and discuss strategies of combining anti-angiogenic therapy and immunotherapy +/− chemotherapy and hypothesize how we can use this strategy for non-small-cell lung cancer in metastatic previously untreated/previously treated settings in previously treated EGFR-mutated NSCLC for the upfront treatment of brain metastases prior to radiation therapy and for the incorporation of this strategy into stage III unresectable disease. We assert the use of anti-angiogenic therapy and immunotherapy when combined appropriately with chemotherapy and radiotherapy has the potential to increase the long-term survivals in both the stage III and metastatic setting so that we can now consider more patients to experience curative treatment.
Open AccessEvaluation of Anti-Angiogenic Therapy Combined with Immunotherapy and Chemotherapy as a Strategy to Treat Locally Advanced and Metastatic Non-Small-Cell Lung Cancer
Immunotherapy has made recent improvements in disease-free survival (DFS) and/or overall survival (OS) in all stages of non-small-cell lung cancer (NSCLC). Here, we review the tumor microenvironment and its immunosuppressive effects and discuss how anti-angiogenic therapies may potentiate the anti-carcinogenic effects of immunotherapy. We also review all the past literature and discuss strategies of combining anti-angiogenic therapy and immunotherapy +/− chemotherapy and hypothesize how we can use this strategy for non-small-cell lung cancer in metastatic previously untreated/previously treated settings in previously treated EGFR-mutated NSCLC for the upfront treatment of brain metastases prior to radiation therapy and for the incorporation of this strategy into stage III unresectable disease. We assert the use of anti-angiogenic therapy and immunotherapy when combined appropriately with chemotherapy and radiotherapy has the potential to increase the long-term survivals in both the stage III and metastatic setting so that we can now consider more patients to experience curative treatment.